CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Increasing the utility of biomarkers in tumour profiling
4.1.2. Availability of funding for cancer research
4.1.3. Increasing number of new cancer cases and increasing demand for personalised
medicine
4.1.5. Growth in use of next-generation sequencing technique for cancer profiling
4.2. Market Restraints & Challenges
4.2.1. Lack of skilled professionals and infrastructure
4.2.2. Unclear regulatory and reimbursement scenario
4.2.3. High capital investments and low benefit ratio for biomarkers
CHAPTER 5. GLOBAL CANCER/TUMOR PROFILING MARKET – BY CANCER
TYPE
5.1. Colorectal Cancer
5.2. Melanoma Cancer
5.3. Prostate Cancer
5.4. Breast Cancer
5.5. Lung Cancer
5.6. Others
CHAPTER 6. GLOBAL CANCER/TUMOR PROFILING MARKET – BY
TECHNOLOGY
6.1. Next Generation Sequencing
6.2. Mass Spectrometry
6.3. Immunoassays
6.4. Hybridization
6.4.1. In situ hybridisation
6.4.2. DNA/RNA Microarray
6.4.3. PCR
6.5. Others
CHAPTER 7. GLOBAL CANCER/TUMOR PROFILING MARKET – BY
APPLICATION
7.1. Research Application
7.2. Clinical Application
7.3. Others
CHAPTER 8. GLOBAL CANCER/TUMOR PROFILING MARKET - BY
GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL CANCER/TUMOR PROFILING MARKET - COMPANY
PROFILES
9.1. Oxford Gene Technology IP Ltd.
9.2. Caris Life Sciences, Inc.
9.3. Nanostring Technologies, Inc.
9.4. Ribomed Biotechnologies, Inc.
9.5. Genomic Health Inc.
9.6. Qiagen N.V.
9.7. Helomics Corporation
9.8. Neogenomics Laboratories, Inc.
9.9. Illumina, Inc.
9.10. HTG Molecular Diagnostics, Inc.
CHAPTER 10. GLOBAL CANCER/TUMOR PROFILING MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
